Zhiyuan Xu

机构：Chinese Academy of Sciences, Zhejiang Cancer Hospital, Nanshan Group (China), Bozhou People's Hospital, Chinese University of Hong Kong, Shenzhen, Cancer Hospital of Chinese Academy of Medical Sciences, University of Hong Kong - Shenzhen Hospital, Shenzhen Second People's Hospital, University of Chinese Academy of Sciences · ORCID：0000-0001-6875-7171

发表论文 90 篇 · 总被引 2757 次 · h-index 28

代表论文

• Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications (2023 · Frontiers in Oncology · 被引 75)
• Burdens of stomach and esophageal cancer from 1990 to 2019 and projection to 2030 in China: Findings from the 2019 Global Burden of Disease Study (2024 · Journal of Global Health · 被引 62)
• Integrative proteomic characterization of adenocarcinoma of esophagogastric junction (2023 · Nature Communications · 被引 48)
• Multi-dimensional cell-free DNA-based liquid biopsy for sensitive early detection of gastric cancer (2024 · Genome Medicine · 被引 31)
• METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics (2024 · Nature Communications · 被引 22)
• Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022 (2024 · BMC Cancer · 被引 21)